Documenting Trofinetide Treatment Phenotypes in Rett Syndrome with a Dual-LLM Consensus Pipeline

arXiv:2610.22062v1 Announce Type: cross Abstract: Objective: Trofinetide, approved in 2023 as the first Rett syndrome treatment, lacks scalable real-world monitoring because chart review is labor-intensive. We developed a dual large language model (LLM) consensus pipeline to extract 18 treatment-response phenotypes, comprising 4 adverse effects, 13 Rett clinical features, and medication refusal, from clinical notes. Materials and Methods: We analyzed 26,763 notes from 108 patients with confirmed sustained trofinetide exposure at Texas Children's Hospital. The pipeline filters notes by keyword, classifies each through two LLMs requiring consensus, and aggregates a patient-by-timepoint matrix. Architecture and prompt were selected on a diarrhea development set, then frozen and applied to the other 17 phenotypes with the phenotype definition substituted, as an out-of-sample test. The reported prompt comparison scores 183 expert-labeled cells. Results: A prompt requiring diarrhea to be active and severe performed best (84.2 $\pm$ 0.0% accuracy; F1 = 0.674), 47 percentage points above regular-expression matching ($p < 0.0001$). Expert reviewers judged six of the pipeline's calls per phenotype, three positive and three negative, and agreed with 90.2% (92/102). The 13 Rett clinical features are manifestations of the disorder itself rather than adverse effects of trofinetide. Gross and fine motor impairment, language/communication, and stereotypy were documented present in 92-100% of patients at every visit. Discussion: In-context LLM extraction captured multi-domain treatment responses. The outcome is documented presence at each visit, not a direction-of-change judgment. Conclusion: Coupling in-context LLM reasoning with a consensus architecture offers a scalable alternative to keyword and regular-expression extraction for real-world evidence, adapting to new phenotypes and medications through configuration alone.

Abstract:Objective: Trofinetide, approved in 2023 as the first Rett syndrome treatment, lacks scalable real-world monitoring because chart review is labor-intensive. We developed a dual large language model (LLM) consensus pipeline to extract 18 treatment-response phenotypes, comprising 4 adverse effects, 13 Rett clinical features, and medication refusal, from clinical notes. Materials and Methods: We analyzed 26,763 notes from 108 patients with confirmed sustained trofinetide exposure at Texas Children's Hospital. The pipeline filters notes by keyword, classifies each through two LLMs requiring consensus, and aggregates a patient-by-timepoint matrix. Architecture and prompt were selected on a diarrhea development set, then frozen and applied to the other 17 phenotypes with the phenotype definition substituted, as an out-of-sample test. The reported prompt comparison scores 183 expert-labeled cells. Results: A prompt requiring diarrhea to be active and severe performed best (84.2 $\pm$ 0.0% accuracy; F1 = 0.674), 47 percentage points above regular-expression matching ($p < 0.0001$). Expert reviewers judged six of the pipeline's calls per phenotype, three positive and three negative, and agreed with 90.2% (92/102). The 13 Rett clinical features are manifestations of the disorder itself rather than adverse effects of trofinetide. Gross and fine motor impairment, language/communication, and stereotypy were documented present in 92-100% of patients at every visit. Discussion: In-context LLM extraction captured multi-domain treatment responses. The outcome is documented presence at each visit, not a direction-of-change judgment. Conclusion: Coupling in-context LLM reasoning with a consensus architecture offers a scalable alternative to keyword and regular-expression extraction for real-world evidence, adapting to new phenotypes and medications through configuration alone.

Quantitative Methods (q-bio.QM); Computation and Language (cs.CL)

arXiv:2610.22062 [q-bio.QM]

(or arXiv:2610.22062v1 [q-bio.QM] for this version)

https://doi.org/10.48550/arXiv.2610.22062 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

analiza aiqbench

Documenting Trofinetide Treatment Phenotypes in Rett Syndrome with a Dual-LLM Consensus Pipeline

Subiecte conexe